TB-500

Technical specifications

Reference specifications describe the material. They do not replace the analytical results for a specific batch.

Chemical name

Thymosin beta-4 (N-terminally acetylated)

Sequence

Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

Molecular formula

C212H350N56O78S

Molecular weight

4963.4 Da

CAS number

77591-33-4

Form

Lyophilized powder

Appearance

White to off-white solid

Purity specification

Declared in the batch certificate

Identity

Declared in the batch certificate

Solubility

Soluble in sterile water and bacteriostatic water

Storage

−20 °C, protected from light

Stability after reconstitution

Keep refrigerated at 2–8 °C and use within the period defined by the laboratory protocol

Batch documentation

Review documentation for the product and variant you are purchasing. A reference specification, a research publication and an individual batch certificate are different sources. Certificate results are accessed with your order details; if documentation is available on request, contact support before relying on it.

Laboratory handling

Reconstitution

Laboratory procedure: allow the closed vial to reach room temperature, disinfect the septum and slowly transfer the diluent against the inner wall of the vial. Do not shake; gently swirl the vial until fully dissolved. Record the volume, diluent and date in the batch log.

Storage

Sealed vial of lyophilized material: store at −20 °C, protected from light and moisture. Avoid repeated freeze-thaw cycles of reconstituted material; aliquot when the experimental design permits.

Protective equipment

Handle in a clean work area with a lab coat, nitrile gloves and eye protection. Dispose of vials, tips and sharps according to the laboratory waste procedure.

Research references

The catalog identifies TB-500 as full-length thymosin beta-4. However, a 2012 analytical study identified the N-terminally acetylated 17–23 fragment of thymosin beta-4 in a product called TB-500 (PMID 22962027). That finding applies to the product analyzed by the authors, not to Pureza's vial. The fragment and the full-length chain must be distinguished before attributing published findings to the declared ingredient.

1. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers

   J Cell Mol Med · 2021 · PMID 34346165

2. Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial

   Cornea · 2015 · PMID 25826322

3. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing

   Ann N Y Acad Sci · 2007 · PMID 17495250

4. Advances in the basic and clinical applications of thymosin β4

   Expert Opin Biol Ther · 2015 · PMID 26096726

5. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations.

   Proc Natl Acad Sci U S A · 1981 · PMID 6940133

6. The sulfoxide of thymosin beta 4 almost lacks the polymerization-inhibiting capacity for actin.

   Eur J Biochem · 1994 · PMID 8055902

Frequently asked questions